Cholangiocarcinoma, Hepatocellular Carcinoma, Metastases, Stereotactic Body Radiotherapy
Conditions
Keywords
liver function, galactose, 18-F-deoxy-galactose, PET/CT, stereotactic body radiation therapy, SBRT
Brief summary
Patients treated with stereotactic radiotherapy for liver tumors undergo PET/CT using the galactose analogue 18-F-deoxy-galactose (FDGal) before and after radiotherapy. This technique provides volumetric mapping of liver function and it allows quantisation of liver function. The method may be used for selection of patients for stereotactic radiotherapy of liver tumors, for determination of radiation induced liver dysfunction and may be included into the treatment planning process of stereotactic radiotherapy.
Interventions
OTHERMeasuring liver function by PET/CT
Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors
Sponsors
Danish Cancer Society
University of Aarhus
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* liver tumor * referred for stereotactic radiation therapy * age \> 18 years
Exclusion criteria
* Impaired kidney function * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Uptake of FDGal | Before, 1 month and 3 months after stereotactic radiotherapy | Volumetric uptake of FDGal can be measured is measured by PET/CT |
Countries
Denmark
Outcome results
None listed